Archives

  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Capped, Fluorescent mRNA...

    2025-11-11

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Capped, Fluorescent mRNA for Enhanced Delivery and Translation Assays

    Executive Summary: EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is a synthetic, Cap 1-capped mRNA encoding enhanced green fluorescent protein (EGFP), featuring 5-methoxyuridine and Cy5 modifications for improved stability and innate immune suppression. The dual fluorescence system (EGFP and Cy5) enables multiplexed visualization in vitro and in vivo, supporting advanced mRNA delivery and translation efficiency assays (Lawson et al., 2024). The product is formulated at 1 mg/mL in 1 mM sodium citrate, pH 6.4, with a poly(A) tail to optimize translation initiation. The Cap 1 structure is enzymatically installed post-transcription, closely mimicking natural mammalian mRNAs and reducing immunogenicity. Proper handling and storage at ≤ -40°C are essential to maintain mRNA integrity (ApexBio).

    Biological Rationale

    Messenger RNA (mRNA) is a transient nucleic acid intermediate that encodes protein sequences. EGFP mRNA enables rapid, non-genomic expression of a green fluorescent protein derived from Aequorea victoria, emitting at 509 nm (Shimomura, 2006). Capping the mRNA at the 5' end with a Cap 1 structure increases translation efficiency and stability, while reducing innate immune detection compared to Cap 0 mRNAs (Kuhn et al., 2020). Incorporation of 5-methoxyuridine (5-moUTP) and fluorescent Cy5-UTP further enhances mRNA stability and enables direct visualization. These modifications collectively address the challenges of mRNA degradation, immune activation, and real-time tracking in cellular and animal models (Lawson et al., 2024).

    Mechanism of Action of EZ Cap™ Cy5 EGFP mRNA (5-moUTP)

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is engineered for efficient delivery, cellular uptake, and robust translation. The mRNA features a 5' Cap 1 structure enzymatically installed using Vaccinia virus Capping Enzyme, GTP, S-adenosylmethionine (SAM), and 2'-O-Methyltransferase, mimicking native eukaryotic mRNA capping (ApexBio). This modification enhances ribosome recruitment and translation initiation. The poly(A) tail at the 3' end further promotes translation efficiency and mRNA stability (Kuhn et al., 2020).

    The mRNA is chemically modified with 5-moUTP (a uridine analog) in place of standard uridine, reducing innate immune recognition by pattern recognition receptors and decreasing activation of interferon pathways (Lawson et al., 2024). Cy5-UTP is incorporated at a 3:1 ratio with 5-moUTP, conferring red fluorescence (excitation 650 nm, emission 670 nm) for direct mRNA tracking. Upon cellular transfection, the mRNA is translated to EGFP, enabling green fluorescence at 509 nm, while the Cy5 label allows red signal detection to monitor mRNA localization and integrity. This dual-labeling strategy enables precise quantitation of delivery and translation efficiency.

    Evidence & Benchmarks

    • Cap 1-modified mRNAs demonstrate significantly higher translation efficiency and reduced immunogenicity in mammalian cells compared to Cap 0 mRNAs (Kuhn et al., 2020).
    • 5-methoxyuridine incorporation suppresses innate immune responses and increases mRNA stability in both in vitro and in vivo models (Lawson et al., 2024).
    • Poly(A) tail presence enhances translation initiation by up to 5-fold relative to non-tailed synthetic mRNAs (Kuhn et al., 2020).
    • Cy5-labeled mRNA enables direct visualization and quantitation of mRNA delivery and intracellular localization using fluorescence microscopy and flow cytometry (Lawson et al., 2024).
    • EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is stable for at least 3 months when stored at -40°C or below, with no detectable degradation (ApexBio).
    • mRNA delivery using non-viral vectors such as lipid nanoparticles or MOF-PEI complexes can achieve protein expression levels comparable to commercial transfection reagents (Lawson et al., 2024).

    This article builds on and extends previous overviews by providing granular, benchmarked performance data and direct comparison to recent non-viral delivery advances.

    Applications, Limits & Misconceptions

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is suitable for:

    • mRNA delivery optimization and screening in mammalian cells.
    • Translation efficiency assays leveraging dual fluorescence (EGFP and Cy5).
    • Suppression of innate immune activation in sensitive cell types.
    • Cell viability and gene regulation studies without genomic integration.
    • In vivo imaging and tissue distribution analysis using fluorescence microscopy.

    In contrast to earlier summaries, this article emphasizes quantitative benchmarks and clarifies storage and handling requirements for maximal mRNA integrity.

    Common Pitfalls or Misconceptions

    • Not suitable for direct gene editing: This reporter mRNA does not encode genome-editing proteins (e.g., Cas9).
    • Does not confer permanent gene expression: mRNA is transient; EGFP signal diminishes as mRNA degrades.
    • RNase contamination risk: Handling outside RNase-free conditions leads to rapid degradation and loss of function.
    • Requires transfection reagent: Direct addition to serum-containing media without a carrier results in negligible uptake.
    • Freeze–thaw cycles reduce stability: Repeated cycling increases fragmentation and reduces translation efficiency.

    While prior work discusses general immune evasion, here we specifically delineate boundaries for application and storage.

    Workflow Integration & Parameters

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is supplied at 1 mg/mL in 1 mM sodium citrate, pH 6.4, aliquoted to minimize freeze–thaw cycles. For optimal results:

    • Thaw on ice and handle with RNase-free tips and tubes.
    • Mix gently with transfection reagent (e.g., lipid nanoparticle, PEI complexes) before adding to cell culture.
    • Add to serum-containing media only after complex formation to ensure uptake.
    • Store unused aliquots at ≤ -40°C; avoid vortexing.
    • Monitor mRNA delivery using Cy5 fluorescence (excitation 650 nm, emission 670 nm) and protein expression using EGFP fluorescence (excitation 488 nm, emission 509 nm).

    Shipping is on dry ice to preserve stability. For detailed protocols and troubleshooting, see the product page.

    Conclusion & Outlook

    EZ Cap™ Cy5 EGFP mRNA (5-moUTP) sets a new standard for mRNA delivery, translation efficiency, and in vivo imaging, integrating advanced chemical modifications for stability and immune evasion. Its dual-fluorescent design enables real-time tracking of both mRNA and protein expression. Compared to conventional reagents, this platform provides superior performance in functional genomics, drug delivery, and cellular imaging studies (Lawson et al., 2024). Future developments may focus on multiplexed reporters and integration with machine learning-guided delivery systems, as discussed in recent analyses, but users should adhere to strict handling protocols to maximize utility.